Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 227

1.

It Takes a Matured mAb to Treat Ebolavirus Infection.

Patel A, Weiner DB.

Cell Host Microbe. 2019 Jan 9;25(1):10-12. doi: 10.1016/j.chom.2018.12.013.

PMID:
30629912
2.

Engineered DNA Vaccination against Follicle-Stimulating Hormone Receptor Delays Ovarian Cancer Progression in Animal Models.

Perales-Puchalt A, Wojtak K, Duperret EK, Yang X, Slager AM, Yan J, Muthumani K, Montaner LJ, Weiner DB.

Mol Ther. 2018 Nov 30. pii: S1525-0016(18)30550-1. doi: 10.1016/j.ymthe.2018.11.014. [Epub ahead of print]

PMID:
30554854
3.

IL-33 delays metastatic peritoneal cancer progression inducing an allergic microenvironment.

Perales-Puchalt A, Svoronos N, Villarreal DO, Zankharia U, Reuschel E, Wojtak K, Payne KK, Duperret EK, Muthumani K, Conejo-Garcia JR, Weiner DB.

Oncoimmunology. 2018 Sep 6;8(1):e1515058. doi: 10.1080/2162402X.2018.1515058. eCollection 2019.

4.

Anti-OspA DNA-Encoded Monoclonal Antibody Prevents Transmission of Spirochetes in Tick Challenge Providing Sterilizing Immunity in Mice.

Wang Y, Esquivel R, Flingai S, Schiller ZA, Kern A, Agarwal S, Chu J, Patel A, Sullivan K, Wise MC, Broderick KE, Hu L, Weiner DB, Klempner MS.

J Infect Dis. 2018 Nov 21. doi: 10.1093/infdis/jiy627. [Epub ahead of print]

PMID:
30476132
5.

Designing consensus immunogens to break tolerance to self-antigens for cancer therapy.

Duperret EK, Yan J, Weiner DB.

Oncotarget. 2018 Oct 30;9(85):35513-35514. doi: 10.18632/oncotarget.26275. eCollection 2018 Oct 30. No abstract available.

6.

Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics.

Khoshnejad M, Patel A, Wojtak K, Kudchodkar SB, Humeau L, Lyssenko NN, Rader DJ, Muthumani K, Weiner DB.

Mol Ther. 2019 Jan 2;27(1):188-199. doi: 10.1016/j.ymthe.2018.10.016. Epub 2018 Nov 15.

PMID:
30449662
7.

In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model.

Patel A, Park DH, Davis CW, Smith TRF, Leung A, Tierney K, Bryan A, Davidson E, Yu X, Racine T, Reed C, Gorman ME, Wise MC, Elliott STC, Esquivel R, Yan J, Chen J, Muthumani K, Doranz BJ, Saphire EO, Crowe JE, Broderick KE, Kobinger GP, He S, Qiu X, Kobasa D, Humeau L, Sardesai NY, Ahmed R, Weiner DB.

Cell Rep. 2018 Nov 13;25(7):1982-1993.e4. doi: 10.1016/j.celrep.2018.10.062.

8.

Protective Efficacy and Long-Term Immunogenicity in Cynomolgus Macaques by Ebola Virus Glycoprotein Synthetic DNA Vaccines.

Patel A, Reuschel EL, Kraynyak KA, Racine T, Park DH, Scott VL, Audet J, Amante D, Wise MC, Keaton AA, Wong G, Villarreal DO, Walters J, Muthumani K, Shedlock DJ, de La Vega MA, Plyler R, Boyer J, Broderick KE, Yan J, Khan AS, Jones S, Bello A, Soule G, Tran KN, He S, Tierney K, Qiu X, Kobinger GP, Sardesai NY, Weiner DB.

J Infect Dis. 2018 Oct 10. doi: 10.1093/infdis/jiy537. [Epub ahead of print]

PMID:
30304515
9.

Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti-CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo.

Duperret EK, Trautz A, Stoltz R, Patel A, Wise MC, Perales-Puchalt A, Smith T, Broderick KE, Masteller E, Kim JJ, Humeau L, Muthumani K, Weiner DB.

Cancer Res. 2018 Nov 15;78(22):6363-6370. doi: 10.1158/0008-5472.CAN-18-1429. Epub 2018 Oct 4.

PMID:
30287678
10.

A Designer Cross-reactive DNA Immunotherapeutic Vaccine that Targets Multiple MAGE-A Family Members Simultaneously for Cancer Therapy.

Duperret EK, Liu S, Paik M, Trautz A, Stoltz R, Liu X, Ze K, Perales-Puchalt A, Reed C, Yan J, Xu X, Weiner DB.

Clin Cancer Res. 2018 Dec 1;24(23):6015-6027. doi: 10.1158/1078-0432.CCR-18-1013. Epub 2018 Sep 27.

PMID:
30262507
11.

Synthetic DNA delivery by electroporation promotes robust in vivo sulfation of broadly neutralizing anti-HIV immunoadhesin eCD4-Ig.

Xu Z, Wise MC, Choi H, Perales-Puchalt A, Patel A, Tello-Ruiz E, Chu JD, Muthumani K, Weiner DB.

EBioMedicine. 2018 Sep;35:97-105. doi: 10.1016/j.ebiom.2018.08.027. Epub 2018 Aug 30.

12.

A Synthetic Micro-Consensus DNA Vaccine Generates Comprehensive Influenza A H3N2 Immunity and Protects Mice Against Lethal Challenge by Multiple H3N2 Viruses.

Elliott STC, Keaton AA, Chu JD, Reed CC, Garman B, Patel A, Yan J, Broderick KE, Weiner DB.

Hum Gene Ther. 2018 Sep;29(9):1044-1055. doi: 10.1089/hum.2018.102.

PMID:
30062926
13.

Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid Immunization.

de La Vega MA, Piret J, Griffin BD, Rhéaume C, Venable MC, Carbonneau J, Couture C, das Neves Almeida R, Tremblay RR, Magalhães KG, Park YK, Roberts CC, Maslow JN, Sardesai NY, Kim JJ, Muthumani K, Weiner DB, Kobinger GP, Boivin G.

J Infect Dis. 2019 Jan 9;219(3):365-374. doi: 10.1093/infdis/jiy336.

PMID:
30053014
14.

Rapid response to an emerging infectious disease - Lessons learned from development of a synthetic DNA vaccine targeting Zika virus.

Kudchodkar SB, Choi H, Reuschel EL, Esquivel R, Jin-Ah Kwon J, Jeong M, Maslow JN, Reed CC, White S, Kim JJ, Kobinger GP, Tebas P, Weiner DB, Muthumani K.

Microbes Infect. 2018 Dec;20(11-12):676-684. doi: 10.1016/j.micinf.2018.03.001. Epub 2018 Mar 17.

15.

Herd immunity: hyperimmune globulins for the 21st century.

Elliott ST, Weiner DB.

Lancet Infect Dis. 2018 Apr;18(4):361-363. doi: 10.1016/S1473-3099(18)30003-3. Epub 2018 Jan 9. No abstract available.

PMID:
29329956
16.

Alteration of the Tumor Stroma Using a Consensus DNA Vaccine Targeting Fibroblast Activation Protein (FAP) Synergizes with Antitumor Vaccine Therapy in Mice.

Duperret EK, Trautz A, Ammons D, Perales-Puchalt A, Wise MC, Yan J, Reed C, Weiner DB.

Clin Cancer Res. 2018 Mar 1;24(5):1190-1201. doi: 10.1158/1078-0432.CCR-17-2033. Epub 2017 Dec 21.

PMID:
29269377
17.

DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections.

Elliott STC, Kallewaard NL, Benjamin E, Wachter-Rosati L, McAuliffe JM, Patel A, Smith TRF, Schultheis K, Park DH, Flingai S, Wise MC, Mendoza J, Ramos S, Broderick KE, Yan J, Humeau LM, Sardesai NY, Muthumani K, Zhu Q, Weiner DB.

NPJ Vaccines. 2017 Jul 6;2:18. doi: 10.1038/s41541-017-0020-x. eCollection 2017.

18.

In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine.

Muthumani K, Griffin BD, Agarwal S, Kudchodkar SB, Reuschel EL, Choi H, Kraynyak KA, Duperret EK, Keaton AA, Chung C, Kim YK, Booth SA, Racine T, Yan J, Morrow MP, Jiang J, Lee B, Ramos S, Broderick KE, Reed CC, Khan AS, Humeau L, Ugen KE, Park YK, Maslow JN, Sardesai NY, Joseph Kim J, Kobinger GP, Weiner DB.

NPJ Vaccines. 2016 Nov 10;1:16021. doi: 10.1038/npjvaccines.2016.21. eCollection 2016.

19.

Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT.

Duperret EK, Wise MC, Trautz A, Villarreal DO, Ferraro B, Walters J, Yan J, Khan A, Masteller E, Humeau L, Weiner DB.

Mol Ther. 2018 Feb 7;26(2):435-445. doi: 10.1016/j.ymthe.2017.11.010. Epub 2017 Nov 21.

PMID:
29249395
20.

Broad cross-protective anti-hemagglutination responses elicited by influenza microconsensus DNA vaccine.

Yan J, Morrow MP, Chu JS, Racine T, Reed CC, Khan AS, Broderick KE, Kim JJ, Kobinger GP, Sardesai NY, Weiner DB.

Vaccine. 2018 May 24;36(22):3079-3089. doi: 10.1016/j.vaccine.2017.09.086.

PMID:
29100705

Supplemental Content

Loading ...
Support Center